File_name,PDF_QA_package,Company_Name
JPM_SRZN_NOTE_11.28.22,PyPDF2_bert-base-uncased,Completed 28 Nov 2022 08:28 PM EST Disseminated 29 Nov
JPM_SRZN_NOTE_11.28.22,PyPDF2_bert-large-uncased,Perella Weinberg
JPM_SRZN_NOTE_11.28.22,PyPDF2_distilbert-base-uncased,"*P
Completed 28 Nov 2022 08"
JPM_SRZN_NOTE_11.28.22,PyPDF2_albert-base-v2,to firm (30)
JPM_SRZN_NOTE_11.28.22,PyPDF2_albert-large-v2,Livescault (jlivescault@pwpartners.com)
JPM_SRZN_NOTE_11.28.22,PyPDF2_google/electra-base-discriminator,vv45a1vtp2hbehar0dfkglwh
JPM_SRZN_NOTE_11.28.22,PyPDF2_google/electra-large-discriminator,Perella Weinberg Partners on Wednesday Jan 25 2023
JPM_SRZN_NOTE_11.28.22,PyPDF2_dmis-lab/biobert-base-cased-v1.1,5)A
JPM_SRZN_NOTE_11.28.22,PyPDF2_allenai/scibert_scivocab_uncased,without the written consent of J.P. Morgan. #$J
JPM_SRZN_NOTE_11.28.22,PyPDF2_emilyalsentzer/Bio_ClinicalBERT,For the exclusive use of Jonathan Livescault
JPM_SRZN_NOTE_11.28.22,PyPDF2_bionlp/bluebert_pubmed_uncased_L-12_H-768_A-12,P
CT one-pager Dec 22,PyPDF2_bert-base-uncased,"Placebo controlled 
iv. Single doseLisa"
CT one-pager Dec 22,PyPDF2_bert-large-uncased,"iii. Placebo controlled 
iv"
CT one-pager Dec 22,PyPDF2_distilbert-base-uncased,"Oxford. 
Expert on"
CT one-pager Dec 22,PyPDF2_albert-base-v2,clock: CT1500 rapidly delivers two potent short -acting adenosine
CT one-pager Dec 22,PyPDF2_albert-large-v2,"level 
iii. Placebo"
CT one-pager Dec 22,PyPDF2_google/electra-base-discriminator,"reprofiling
•Aarti Jagannath"
CT one-pager Dec 22,PyPDF2_google/electra-large-discriminator,lisa.stone@circadiantherapeutics
CT one-pager Dec 22,PyPDF2_dmis-lab/biobert-base-cased-v1.1,.circadiantherapeutics
CT one-pager Dec 22,PyPDF2_allenai/scibert_scivocab_uncased,"•Nick Dixon -Clegg, NED
•Glenn Leighton"
CT one-pager Dec 22,PyPDF2_emilyalsentzer/Bio_ClinicalBERT,"Oxford. 
Expert on neuroscience, drug 
screening,"
CT one-pager Dec 22,PyPDF2_bionlp/bluebert_pubmed_uncased_L-12_H-768_A-12,"022 
www.circadiantherapeutics"
JPM_SRZN_NOTE_11.28.22,pdfminer_bert-base-uncased,redistributed
JPM_SRZN_NOTE_11.28.22,pdfminer_bert-large-uncased,"*P
Completed 28 Nov 2022 08:28 PM"
JPM_SRZN_NOTE_11.28.22,pdfminer_distilbert-base-uncased,"Securities and 
Exchange Commission of Pakistan"
JPM_SRZN_NOTE_11.28.22,pdfminer_albert-base-v2,"Australia’s 
Research Independence Policy which can be found"
JPM_SRZN_NOTE_11.28.22,pdfminer_albert-large-v2,"research report at  http://www.jpmorganmarkets.com,"
JPM_SRZN_NOTE_11.28.22,pdfminer_google/electra-base-discriminator,"any 
jurisdiction.
""Other Disclosures"" last revised November"
JPM_SRZN_NOTE_11.28.22,pdfminer_google/electra-large-discriminator,may
JPM_SRZN_NOTE_11.28.22,pdfminer_dmis-lab/biobert-base-cased-v1.1,Morgan
JPM_SRZN_NOTE_11.28.22,pdfminer_allenai/scibert_scivocab_uncased,the written consent of J.P. Morgan
JPM_SRZN_NOTE_11.28.22,pdfminer_emilyalsentzer/Bio_ClinicalBERT,Singapore in respect of any matters
JPM_SRZN_NOTE_11.28.22,pdfminer_bionlp/bluebert_pubmed_uncased_L-12_H-768_A-12,redistributed
CT one-pager Dec 22,pdfminer_bert-base-uncased,study will cost $4.4m; will be completed
CT one-pager Dec 22,pdfminer_bert-large-uncased,"time
Therapeutic dose ranging

-

Protocol: 

i.
ii.
iii"
CT one-pager Dec 22,pdfminer_distilbert-base-uncased,Primary
CT one-pager Dec 22,pdfminer_albert-base-v2,"veterans) all of whom 
directly"
CT one-pager Dec 22,pdfminer_albert-large-v2,"CT-1500-02 Phase IB (Healthy subjects)
-

Phase"
CT one-pager Dec 22,pdfminer_google/electra-base-discriminator,.com
CT one-pager Dec 22,pdfminer_google/electra-large-discriminator,"Delay: 1 drug level 
Placebo controlled 
Single dose

www"
CT one-pager Dec 22,pdfminer_dmis-lab/biobert-base-cased-v1.1,cost $4.4m
CT one-pager Dec 22,pdfminer_allenai/scibert_scivocab_uncased,iv
CT one-pager Dec 22,pdfminer_emilyalsentzer/Bio_ClinicalBERT,prescribers
CT one-pager Dec 22,pdfminer_bionlp/bluebert_pubmed_uncased_L-12_H-768_A-12,"whom 
directly engage with governments"
